Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triptorelin + fsh + lh
- Development stage
- Unknown
- Lead developer
- Debiopharm
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
A combination drug regimen used in assisted reproductive technology (ART) for women with female infertility, specifically those identified as "poor responders" undergoing in vitro fertilization (IVF). This regimen, often referred to as a "microdose GnRH agonist" or "flare" protocol, consists of triptorelin (a gonadotropin-releasing hormone agonist), recombinant follicle-stimulating hormone (FSH), and recombinant luteinizing hormone (LH). Triptorelin is administered in small doses to exploit the initial "flare" effect of endogenous gonadotropins and subsequently desensitize the pituitary gland to prevent a premature LH surge. Exogenous recombinant FSH and LH are administered concurrently to directly stimulate the development and maturation of multiple ovarian follicles. This specific combination and protocol were evaluated by Bioroma in clinical studies to compare its efficacy against other stimulation regimens, such as clomiphene citrate-based protocols, in patients with a poor prognosis for ovarian response.
- Other names
- Microdose GnRH agonist protocolTriptorelin plus daily FSH and LH
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on triptorelin + fsh + lh.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triptorelin + fsh + lh.